Physician profile
Steven Treon
NPI 1821060138
$366,328.06
in general payments reported to CMS, 2019-2025
18 companies · $93K in 2025
The $93K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $17K · 2021: $55K · 2022: $30K · 2023: $28K · 2024: $79K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $199K · Food and Beverage: $882 · Travel and Lodging: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $199,025.00 |
| Food and Beverage | $882.22 |
| Travel and Lodging | $277.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $196,362.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $33,075.00 | 2019-2021 | |
| Beigene Switzerland Gmbh | $28,825.69 | 2021-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $24,973.38 | 2019-2021 | |
| Beigene USA, INC. | $17,993.09 | 2020-2024 | Brukinsa |
| Janssen Global Services, LLC | $13,960.00 | 2020-2021 | |
| Celgene Corporation | $9,985.61 | 2019 | |
| Janssen Biotech, INC. | $9,053.77 | 2019-2024 | Imbruvica, Darzalex, Talvey |
| Beigene, LTD. | $8,165.90 | 2020-2023 | |
| Beigene (Suzhou) Co., LTD. | $6,500.00 | 2022 | |
| Beone Medicines USA, INC. | $5,729.95 | 2025 | Brukinsa |
| Abbvie INC. | $3,850.00 | 2020 | |
| Merck Sharp & Dohme LLC | $3,500.00 | 2021 | |
| Astrazeneca Uk Limited | $3,280.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $802.89 | 2023-2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $145.30 | 2025 | |
| Eli Lilly and Company | $124.98 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Treon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.